<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250223</url>
  </required_header>
  <id_info>
    <org_study_id>F2-study</org_study_id>
    <nct_id>NCT01250223</nct_id>
  </id_info>
  <brief_title>Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)</brief_title>
  <official_title>F2-PROTOCOL: Prospective Collection of Data of Possible Prognostic Relevance in Patients With Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Angela Serra per la ricerca sul cancro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Follicular Lymphoma Prognostic Factor Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Associazione Angela Serra per la ricerca sul cancro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The F2-study is a complement of the previous studies of the Follicular Lymphoma Prognostic
      Factors Project which permitted the development of the Follicular Lymphoma International
      Prognostic Index (FLIPI).

      The F2-study is designed as a prospective collection of information potentially useful to
      predict the prognosis of newly diagnosed Follicular Lymphoma patients, and its purposes are
      to validate the FLIPI and to verify whether a prognostic collection of data would allow the
      development of a more accurate prognostic index.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      So far, in patients with lymphoma a variety of studies aimed at the evaluation of prognosis
      have been conducted. In particular, different demographic, clinical and biological factors
      have shown a prognostic role in univariate and multivariate analysis, including age, gender,
      stage, tumor burden, bone marrow involvement, systemic symptoms, Performance status, serum
      lactate dehydrogenase (LDH) level, anemia, erythrocyte sedimentation rate (ESR) and beta-2
      microglobulin.

      The combination of those parameters has allowed the identification of several prognostic
      scores.

      Attempts to define prognosis in follicular lymphomas begun in the late '70s. Then, when in
      1993 the International Prognostic Index (IPI) was defined for aggressive lymphomas it was
      also applied to low-grade lymphomas leading to conflicting results, and the need for a
      prognostic index specifically designed for follicular lymphomas emerged.

      A large study on prognosis in patients with follicular lymphoma was performed by the Italian
      Lymphoma Intergroup that leaded to the definition of the Italian Lymphoma Intergroup (ILI)
      score, based on 987 patients (Federico M et al. Blood 2000; 95(3):783-789). In 2004 the
      Follicular Lymphoma International Prognostic Project allowed the definition of a new score on
      4167 pts with follicular lymphoma, the Follicular Lymphoma International Prognostic Index
      (FLIPI) (Solal-Céligny P et al. Blood 2004;104(5):1258-1265). This score is based on the
      evaluation of age (younger than 60 years vs 60 years or older), Ann Arbor stage (I-II vs
      III-IV), number of nodal sites (0-4 vs &gt; 5 or more), Hemoglobin (Hb)level (greater than or
      equal 12g/dL vs lower than 12g/dL), serum Lactate Dehydrogenase (LDH) (normal vs elevated)
      and identifies three main groups of patients with different survival:low risk (0-1 factors);
      intermediate risk (2 factors); high risk (3-5 factors).

      Notwithstanding the huge number of patients considered in these studies, all mentioned
      prognostic scores (IPI, ILI and FLIPI) are based on a retrospective analysis of archive data.
      This approach can introduce biases that can hamper final results. A first problem is the
      selection of patients that can be influenced by single institution policy and patient's or
      physician's related factors. Furthermore, some important variables, such as
      beta2-microglobulin or Erythrocyte Sedimentation Rate (ESR), that have frequently shown a
      high prognostic significance in univariate analysis, are hardly included in the final indexes
      because they are available only in a small number of patients thus loosing their value in
      multivariate analysis. Then, lacking homogeneous and prospectively defined criteria,
      retrospective evaluation of some study parameter as for example clinical response cannot be
      easily defined and all derived endpoints such as Failure Free Survival (FFS)or Progression
      Free Survival (PFS) may be biased.

      Finally the results of a retrospective analysis aiming at the evaluation of survival are
      dependent on the type of administered treatment and with the recent advent of new drugs such
      as monoclonal antibodies and purine analogs that can be used also in the elderly patients the
      role of some established prognostic factor may have changed.

      These are the reasons why we thought it would be useful to start a new study based on the
      prospective registration in a short period of time of patients with follicular lymphoma for
      whom it would be possible collect an exhaustive set of clinical data and biological
      information.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2003</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Free Survival</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1093</enrollment>
  <condition>Lymphoma, Follicular</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed tissue for central diagnostic pathology review
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Previously-untreated patients with de novo diagnosis of Follicular Lymphoma according to
        World Health Organization (WHO) classification (grade 1,2,3a,3b)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed follicular lymphoma

          -  Patients with histologically confirmed diagnosis of follicular lymphoma according to
             WHO classification (any grade)

          -  Age over 18

          -  Written informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Federico, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dip. Oncologia, Ematologia e Patologie dell'Apparato Respiratorio - Università di Modena e Reggio Emilia, Modena, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Solal-Céligny, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Jean Bernard, Le Mans, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armando Lopez-Guillermo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut d'Hematologia i Oncologia, Hospital Clinic, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter McLaughlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Ctr, Houston, TX, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Umberto Vitolo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Universitaria Ospedaliera San Giovanni Battista, Torino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano A. Pileri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Seragnoli, Unità Operativa di Emolinfopatologia, Università di Bologna, Bologna, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine - Department of Hematology/Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academia Nacional de Medicina - Oncohematology Department, Instituto de Investigaciones Hematologicas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Internacion e Investigacion Clinica &quot;Angelica Ocampo&quot; - Hematologia</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University General Hospital - Ist Dept Medicine</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire - Hématologie</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié Comprehensive Cancer Center</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard, Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Univeristaire - Hématologie clinique</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital caremeau - Service de Medecine Interne B</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau - Oncologie medicale</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda O.U. Vittorio Emanuele-Ferrarotto-S. Bambino</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese-Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza IRCCS</name>
      <address>
        <city>S. Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale unico Versilia USL 12 - Divisione di Medicina II, DH Oncoematologico</name>
      <address>
        <city>Lido di Camaiore</city>
        <state>Lucca</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Vincenzo - Ematologia e Immunologia</name>
      <address>
        <city>Taormina</city>
        <state>Messina</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Universitario San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Univ. di Modena e Reggio Emilia - Ematologia</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Univ. di Modena e Reggio Emilia - Medicina Interna</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Univ. di Modena e Reggio Emilia - Oncologia II</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Madonna delle Grazie</name>
      <address>
        <city>Matera</city>
        <state>MT</state>
        <zip>75100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena</name>
      <address>
        <city>Palermo</city>
        <state>Pa</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale civile Guglielmo da Saliceto - Medicina Oncologica ed Ematologica</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santo Spirito, USL di Pescara - Dipartimento di Oncologia</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Monteluce - Divisione di Clinica Medica</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana - UO di Ematologia</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo - Clinica Ematologica</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Carlo - Oncologia Medica</name>
      <address>
        <city>Potenza</city>
        <state>PZ</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi-Melacrino-Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Morelli - Divisione di Medicina Generale, Ematologia</name>
      <address>
        <city>Sondalo</city>
        <state>Sondrio</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario a gestione diretta - Divisione di Ematologia</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Giovanni e Paolo - UO di Ematologia</name>
      <address>
        <city>Venezia</city>
        <state>VE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea - UOC Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Eugenio - Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università la Sapienza, Dip. di Biotecnologie Cellulari ed Ematologia, Sez. Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol - Institut Català d'Oncologia</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic - Institut d'Hematologia i Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall de Hebron - Servei d'Hematologia Clinica</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institu Catala d'Oncologia - Servei d'Hematologia</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <state>TI</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barths and The London NHS Trust</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Federico M, Bellei M, Pro B, Lopez-Guillermo A, Marcheselli L, Trneny M, Soubeyran P, MCLaughlin P, Pileri S, Solal-Céligny P on behalf of the F2 study. Revalidation of FLIPI in patients with Follicular Lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. J Clin Oncol 25(18s), 2007. Abstr 8008.</citation>
  </results_reference>
  <results_reference>
    <citation>Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Martelli M, Soubeyran P, Cortelazzo S, Martinelli G, Pileri S, McLaughlin P, Solal-Céligny P on behalf of International Follicular Lymphoma Prognostic factor Project (IFLPFP) F2-study group. F2 prognostic index. Ann Oncol 19(suppl 4):101-102, 2008. Abstr 058.</citation>
  </results_reference>
  <results_reference>
    <citation>Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009 Sep 20;27(27):4555-62. doi: 10.1200/JCO.2008.21.3991. Epub 2009 Aug 3.</citation>
    <PMID>19652063</PMID>
  </results_reference>
  <results_reference>
    <citation>Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012 Nov 1;30(31):3848-53. doi: 10.1200/JCO.2010.33.4474. Epub 2012 Sep 24.</citation>
    <PMID>23008294</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma, Follicular</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Progression-Free Survival</keyword>
  <keyword>Outcome</keyword>
  <keyword>International Cooperation</keyword>
  <keyword>Data Collection</keyword>
  <keyword>Prospective studies</keyword>
  <keyword>Rare Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

